Table 1:
Demographic and clinical characteristics by inclusion in rapid antigen test analysis
| Not in analysis | In analysis | |
|---|---|---|
| n * | 534 | 727 |
| Age, y, median (IQR) | 73 (49–76) | 73 (50–76) |
| Cohort, no. (%) | ||
| 30–50 years old | 167 (31.3) | 202 (27.8) |
| ≥70 years old | 367 (68.7) | 525 (72.2) |
| Female or non-binary, no. (%) | 281 (60.8) | 482 (66.3) |
| Caucasian, no. (%) | 391 (84.6) | 656 (90.2) |
| Diabetes, no. (%) | 62 (13.4) | 64 (8.8) |
| Cardiovascular disease, no. (%) | 186 (40.3) | 241 (33.1) |
| Chronic obstructive pulmonary disease, no. (%) | 7 (1.5) | 15 (2.1) |
| Asthma, no. (%) | 51 (11.0) | 72 (9.9) |
| Cancer, no. (%) | 60 (13.0) | 120 (16.5) |
| Smoking, no. (%) | ||
| Never | 248 (53.7) | 421 (57.9) |
| Not anymore | 173 (37.4) | 281 (38.7) |
| Yes | 41 (8.9) | 25 (3.4) |
| Body mass index†, median (IQR) | 27.0 (23.6–30.9) | 25.8 (23.2–29.1) |
| No. (%) of vaccine doses | ||
| 1 | 14 (3.0) | 1 (0.1) |
| 2 | 163 (35.3) | 24 (3.3) |
| 3 | 285 (61.7) | 702 (96.6) |
| Vaccine type‡, no. (%) | ||
| BNT162b2 only | 222 (49.6) | 353 (48.6) |
| mRNA1273 only | 53 (11.8) | 63 (8.7) |
| BNT162b2 and mRNA1273 | 136 (30.4) | 237 (32.6) |
| Other or unknown | 37 (8.3) | 73 (10.1) |
| Weeks between dose 1 and 2§, median (IQR) | 10.1 (7.9–12.1) | 10.4 (8.3–11.7) |
* 1189 (94%) of those invited to participate in the sub-study completed the baseline questionnaire
† Body mass index was missing for 17/1189 (1.4%)
‡ For 1174 participants who received two or three doses
§ 2nd dose date was missing for 5/1174 (0.4%)